{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069794","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.236742+00:00","generated_at":"2026-05-21T16:19:31.151769+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025","bullets":["Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.","Cash and equivalents $12.7M at March 31, 2025; extended runway into 2026 via $5M registered direct offering and ~$1M ATM proceeds.","Preparing for potential launch of ORLYNVAH (oral sulopenem) for uUTIs by Q4 2025; FDA approved October 2024.","Repaid $6.5M 6.500% exchangeable senior subordinated notes due 2025 in January 2025.","R&D expense fell to $0.6M (from $4.0M) due to REASSURE trial wind-down; G&A rose to $2.8M on pre-commercialization costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069794","json":"https://secwatch.observer/filing/0000950170-25-069794.json","markdown":"https://secwatch.observer/filing/0000950170-25-069794.md","text":"https://secwatch.observer/filing/0000950170-25-069794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/0000950170-25-069794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/itrm-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:19:31.151769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}